UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549


                                   FORM 10-QSB


          QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934


                      FOR THE QUARTER ENDED MARCH 31, 2005


                             COMMISSION FILE NUMBER:


                             BV PHARMACEUTICAL, INC.
             ______________________________________________________
             (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)


                                     NEVADA
         ______________________________________________________________
         (State or other jurisdiction of incorporation or organization)


        Nevada                                           72-1580091
_______________________                     ____________________________________
(State of organization)                     (I.R.S. Employer Identification No.)


                           2890 Vassar Street, Suite A
                                 Reno, NV 89502

                    ________________________________________
                    (Address of principal executive offices)


                                Tel: 775.352.4160
                _________________________________________________
                Registrants telephone number, including area code


Check  whether the issuer (1) filed all reports  required to be filed by Section
13 or 15(d) of the  Exchange  Act  during  the past 12  months  and (2) has been
subject to such filing  requirements  for the past 90 days.  Yes [x]  Securities
registered under Section 12(g) of the Exchange Act:

There are 37,480,100 shares of common stock outstanding as of March 31, 2005


                                       1


<PAGE>


                                TABLE OF CONTENTS

                                                                            PAGE

PART I       FINANCIAL INFORMATION                                            3

ITEM  1      FINANCIAL STATEMENTS                                             3

ITEM  2      MANAGEMENT'S DISCUSSION OF OPERATIONS AND
             FINANCIAL CONDITION                                             10

PART II      OTHER INFORMATION                                               17

ITEM 6       EXHIBITS AND REPORTS ON FORM 8-K                                17

ITEM 7       SIGNATURES                                                      17


                                       2


<PAGE>


                                     PART I

                             FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS









                             BV PHARMACEUTICAL, INC.

                          (A Development Stage Company)

                          INTERIM FINANCIAL STATEMENTS

                      March 31, 2005 and December 31, 2004

                             (Stated in US Dollars)

                                   (Unaudited)


                                       3










<PAGE>

<TABLE>
<CAPTION>

                             BV PHARMACEUTICAL, INC.
                          (A Development Stage Company)
                             INTERIM BALANCE SHEETS
                      March 31, 2005 and December 31, 2004
                             (Stated in US Dollars)
                                   (Unaudited)

                                                                     March 31,     December 31,
                                                                       2005            2004
                                                                     _________     ____________
<S>                                                                  <C>            <C>
                                     ASSETS

Current
   Cash                                                              $  11,914      $  24,964
   Accounts receivable                                                   2,000          2,000
                                                                     _________      _________

                                                                     $  13,914      $  26,964
                                                                     =========      =========

LIABILITIES

Current
   Accounts payable and accrued liabilities                          $   8,690      $   8,517
   Current portion of convertible debentures - Note 3                   50,000         50,000
                                                                     _________      _________

                                                                        58,690         58,517

Convertible debentures - Note 3                                          6,025          4,792
                                                                     _________      _________

                                                                        64,715         63,309
                                                                     _________      _________

STOCKHOLDERS' DEFICIENCY

Capital stock - Notes 3 and 4
   Authorized:  75,000,000 common shares, $0.001 par value
   Issued:  37,480,100 shares (December 31, 2004:  37,480,100)          37,480         37,480
Additional paid-in capital                                              62,495         62,495
Deficit accumulated during the development stage                      (150,776)      (136,320)
                                                                     _________      _________

                                                                       (50,801)       (36,345)
                                                                     _________      _________

                                                                     $  13,914      $  26,964
                                                                     =========      =========


                             SEE ACCOMPANYING NOTES


                                       4

</TABLE>


<PAGE>

<TABLE>
<CAPTION>

                             BV PHARMACEUTICAL, INC.
                          (A Development Stage Company)
                        INTERIM STATEMENTS OF OPERATIONS
               for the three month period ended March 31, 2005 and
               2004 and for the period from June 30, 2000 (Date of
                        Incorporation) to March 31, 2005
                             (Stated in US Dollars)
                                   (Unaudited)


                                                                                  June 30, 2000
                                                                                     (Date of
                                                                                  Incorporation)
                                                    Three months ended                  to
                                                         March 31,                  March 31,
                                                 2005               2004               2005
                                               ___________       ___________      ______________
<S>                                            <C>               <C>                <C>

Revenue
   Licence fees                                $         -       $     6,000        $  24,000
   Other income                                        480                 -            1,738
                                               ___________       ___________        _________

                                                       480             6,000           25,738
                                               ___________       ___________        _________

General and administrative expenses
   Advertising and promotion                             -                 -            1,001
   Consulting fees                                       -             1,500           48,072
   Filing fees                                       5,047             1,367            9,798
   Interest and bank charges                         1,288             1,141            6,293
   Investor relations                                    -                 -            9,996
   Office and miscellaneous                          2,279               800            9,425
   Marketing research and development                    -                 -           10,000
   Professional fees                                 5,222             2,885           28,468
   Rent                                                  -                 -              505
   Transfer agent fees                               1,100                 -            1,100
   Intellectual property acquisition costs               -                 -           50,000
   Website                                               -                 -            1,856
                                               ___________       ___________        _________

                                                    14,936             7,693          176,514
                                               ___________       ___________        _________

Net loss for the period                        $   (14,456)      $    (1,693)       $(150,776)
                                               ===========       ===========        =========

Basic loss per share                           $     (0.00)      $     (0.00)
                                               ===========       ===========

Weighted average number of
 shares outstanding                             37,480,100        37,480,100
                                               ===========       ===========


                             SEE ACCOMPANYING NOTES


                                       5

</TABLE>


<PAGE>

<TABLE>
<CAPTION>


                             BV PHARMACEUTICAL, INC.
                          (A Development Stage Company)
                        INTERIM STATEMENTS OF CASH FLOWS
               for the three month period ended March 31, 2005 and
               2004 and for the period from June 30, 2000 (Date of
                        Incorporation) to March 31, 2005
                             (Stated in US Dollars)
                                   (Unaudited)


                                                                                  June 30, 2000
                                                                                     (Date of
                                                                                  Incorporation)
                                                    Three months ended                  to
                                                         March 31,                  March 31,
                                                 2005               2004               2005
                                               ___________       ___________      ______________
<S>                                            <C>               <C>                <C>

Cash flows used in Operating Activities
   Net loss for the period                     $   (14,456)      $    (1,693)       $(150,776)
   Changes in non-cash working capital
    balances related to operations:
      Accounts receivable                                -                 -           (2,000)
      Accounts payable and accrued liabilities         173               385            8,690
      Unearned revenue                                   -             1,000                -
                                               ___________       ___________        _________

                                                   (14,283)             (308)        (144,086)
                                               ___________       ___________        _________

Cash flows from Financing Activities
   Capital stock issued                                  -                 -           99,975
   Increase in convertible debentures                1,233            51,038           56,025
                                               ___________       ___________        _________

                                                     1,233            51,038          156,000
                                               ___________       ___________        _________

Increase (decrease) in cash                        (13,050)           50,730           11,914

Cash, beginning of the period                       24,964             3,708                -
                                               ___________       ___________        _________

Cash, end of the period                        $    11,914       $    54,438        $  11,914
                                               ===========       ===========        =========

Supplemental disclosure of cash flow
   information Cash paid for:
      Interest                                 $         -       $         -        $       -
                                               ===========       ===========        =========

      Income taxes                             $         -       $         -        $       -
                                               ===========       ===========        =========


                             SEE ACCOMPANYING NOTES


                                       6

</TABLE>


<PAGE>

<TABLE>
<CAPTION>


                             BV PHARMACEUTICAL, INC.
                          (A Development Stage Company)
                              INTERIM STATEMENT OF STOCKHOLDERS' EQUITY
                      (DEFICIENCY) for the period June 30, 2000 (Date of
                      Incorporation) to March 31, 2005
                             (Stated in US Dollars)
                                   (Unaudited)

                                                                                                      Deficit
                                                                                                    Accumulated
                                                                                     Additional     During the
                                                             Common Stock             Paid-in       Development
                                                       *Shares       **Par Value      Capital          Stage         Total
                                                      __________     ___________     __________     ___________     ________
<S>                                                   <C>             <C>             <C>            <C>            <C>

Capital stock subscribed pursuant to an offering
 memorandum for cash              - at $0.000007      30,543,000      $ 30,543        $(30,339)      $       -      $    204
                                                      __________      ________        ________       _________      ________

Balance, December 31, 2000                            30,543,000        30,543         (30,339)              -           204

Capital stock issued pursuant to a private
 placement                            - at $0.01       6,777,100         6,777          60,994               -        67,771
                                      - at $0.20          40,000            40           7,960               -         8,000
Net loss for the year                                          -             -               -         (69,885)      (69,885)
                                                      __________      ________        ________       _________      ________

Balance, December 31, 2001                            37,360,100        37,360          38,615         (69,885)         6,090
Capital stock issued pursuant to a private
 placement                            - at $0.20         120,000           120          23,880               -        24,000
Net loss for the year                                          -             -               -         (30,090)      (30,090)
                                                      __________      ________        ________       _________      ________

Balance, December 31, 2002                            37,480,100        37,480          62,495         (99,975)            -
Net income for the year                                        -             -               -             108           108
                                                      __________      ________        ________       _________      ________

Balance, December 31, 2003                            37,480,100        37,480          62,495         (99,867)
Net loss for the year                                          -             -               -         (36,453)      (36,453)
                                                      __________      ________        ________       _________      ________

Balance, December 31, 2004                            37,480,100        37,480          62,495        (136,320)      (36,345)
Net loss for the period                                        -             -               -         (14,456)      (14,456)
                                                      __________      ________        ________       _________      ________

Balance, March 31, 2005                               37,480,100      $ 37,480        $ 62,495       $(150,776)     $(50,801)
                                                      ==========      ========        ========       =========      ========

*  The common stock issued has been retroactively  restated to reflect a forward
   stock split of 1,500 new shares for one old share effective on January 5,
   2001.

** The par value of common  stock has been  retroactively  restated to reflect a
   change from no par value to a par value of $0.001 per share.


                             SEE ACCOMPANYING NOTES


                                       7

</TABLE>


<PAGE>


                             BV PHARMACEUTICAL, INC.
                          (A Development Stage Company)
                    NOTES TO THE INTERIM FINANCIAL STATEMENTS
                      March, 31, 2005 and December 31, 2004
                             (Stated in US Dollars)
                                   (Unaudited)


Note 1        INTERIM REPORTING

              The accompanying unaudited interim financial statements have been
              prepared by BV Pharmaceuticals, Inc. (the "Company") pursuant to
              the rules and regulations of the United States Securities and
              Exchange Commission. Certain information and disclosures normally
              included in annual financial statements prepared in accordance
              with accounting principles generally accepted in the United States
              of America have been condensed or omitted pursuant to such rules
              and regulations. In the opinion of management, all adjustments and
              disclosures necessary for a fair presentation of these financial
              statements have been included. Such adjustments consist of normal
              recurring adjustments. These interim financial statements should
              be read in conjunction with the audited financial statements of
              the Company for the fiscal year ended December 31, 2004.

              The results of operations for the three months ended March 31,
              2005 are not indicative of the results that may be expected for
              the full year.

Note 2        CONTINUANCE OF OPERATIONS

              The interim financial statements have been prepared using
              generally accepted accounting principles in the United States of
              America applicable for a going concern which assumes that the
              Company will realize its assets and discharge its liabilities in
              the ordinary course of business. At March 31, 2005, the Company
              has a working capital deficiency of $44,776, has not yet attained
              profitable operations and has accumulated losses of $150,776 since
              its commencement. Its ability to continue as a going concern is
              dependent upon the ability of the Company to generate profitable
              operations in the future and/or to obtain the necessary financing
              to meet its obligations and pay its liabilities arising from
              normal business operations when they come due. The outcome of
              these matters cannot be predicted with any certainty at this time
              and raise substantial doubt that the Company will be able to
              continue as a going concern. These financial statements do not
              include any adjustments to the amounts and classification of
              assets and liabilities that may be necessary should the Company be
              unable to continue as a going concern. The Company anticipates
              that additional funding will be in the form of equity financing
              from the sale of common shares. The Company may also seek to
              obtain short-term loans from the directors of the Company. There
              are no current arrangements in place for equity funding or
              short-term loans.


                                       8


<PAGE>


Note 3        CONVERTIBLE DEBENTURES

<TABLE>
<CAPTION>
                                                           March 31,     December 31,
                                                             2005            2004
                                                           ________      ____________
<S>                                                        <C>            <C>
            On January 15, 2004 the Company issued two
            convertible debentures in the principal
            amount of $25,000 each bearing interest at
            10% per annum and secured by the general
            credit of the Company. These debentures
            are convertible into common shares of the
            Company on the basis of $0.20 per common
            share for each $1 of principal and
            interest accrued thereon, at the option of
            the debenture holder, up to January 15,
            2006. Interest shall be payable at the end
            of each calendar year with the first
            payment due on December 31, 2007, in
            either cash or common shares at the option
            of the holder. If the interest is paid in
            shares, then the shares will have a deemed
            value of $2.50 each.                           $ 56,025       $ 54,792

            Less: current portion                           (50,000)       (50,000)
                                                           ________       ________
                                                           $  6,025       $  4,792
                                                           ========       ========

</TABLE>


Note 4        CAPITAL STOCK - Note 3

              On January 5, 2001, the Company approved a forward split of its
              common stock on the basis of 1,500 new for 1 old. The number of
              shares referred to in these financial statements has been restated
              wherever applicable to give retroactive effect on the forward
              stock split.

              On May 25, 2004, the Company amended its authorized capital stock
              to 75,000,000 common shares with a par value of $0.001 per share.
              The number of authorized shares and the par value per share as
              referred to in these financial statements has been restated
              wherever applicable to give retroactive effect to this amendment.


                                       9


<PAGE>


ITEM  2      MANAGEMENT'S DISCUSSION OF OPERATIONS AND FINANCIAL CONDITION

DESCRIPTION OF BUSINESS

BV Pharmaceutical, Inc. is a Nevada corporation, which was originally formed on
June 30, 2000 under the name of All Printer Supplies.com. As All Printer
Supplies.com, the company sought a consulting opportunity for products and
supplies to be offered on the internet, but the economy at the time, due the
demise of many "dot com" companies and businesses, and the poor market
conditions, was never able to launch its business. On April 17, 2003, the
Company changed its name to BV Pharmaceutical, Inc. Its principal place of
business is located at 2890 Vassar Street, Suite A, Reno, NV 89502. The Company
was organized to engage in any lawful corporate business. BV Pharmaceutical,
Inc., has been in the developmental stage since inception and has a very limited
operating history and limited revenues. The Company has a fully developed
business plan, is operational and receiving revenue. The company has $176,514 in
expenses to date.

BV Pharmaceutical, Inc has limited start-up operations and is considered a
development stage Company. The Company was originally capitalized at 100,000,000
shares of Common Stock, with no par value. On May 25, 2004 the amended Articles
of Incorporation were filed with the state of Nevada to decrease the number of
authorized capital stock to 75,000,000 common shares with $0.001 par value. By
reducing the number of shares and establishing a par values for the shares, the
Company's annual filing fee with the Nevada Secretary of State was reduced. The
amendment was a cost-saving measure only. The only impact on the shareholders
was a reduction of the total authorized shares. While this reduced the shares
available for issuance, it also limited the possible dilution which could be
suffered by the shareholders. The Company believes the amendment had no material
impact on the Company, its operations, proposed operations or the rights of
shareholders.

In an effort to develop our business, we will seek to establish strategic
business relationships with leading firms. We anticipate these strategic
relationships would involve the offering of our services to the members and
employees of the particular company on a discounted basis. We have not yet
established the amount of any such discount. Initially we intend to focus our
efforts on offering these services to companies in the Entertainment, Sports,
and Biotech industries. We have not yet identified, contacted or establish any
relationships with any these companies.

BUSINESS DEVELOPMENT.

We were incorporated in the State of Nevada on June 30, 2000, for the purpose of
providing consulting services to businesses, and engaging in any other lawful
activity.

PRINCIPAL PRODUCTS AND SERVICES

We currently have a web site at the URL www.yourcloneguard.com. We have
registered a domain name, and have a hosting service for www.yourcloneguard.com.
Our Company and website provide information and services in the areas of
personal DNA collection, analysis, profiling, banking and DNA profile database
maintenance.

The website provides interested parties: services, information and resources
dealing with the collection, analysis, protection and banking of ones personal
and unique DNA profile. The website is fully operational, provides access to the
services discussed above, and allows interested parties to place orders. The
company's website is limited to the services discussed above. Through our
website, you will find information on such topics and issues as: DNA, DNA
Patterns or Profiles, DNA patents, DNA sample collection, confidentiality
aspects of DNA profile collection, DNA collection and banking suitability for
minors, DNA cloning, theft and protection issues. In addition you will find
links to other articles and resources of interest.

Through its website the Company offers access to services for personal DNA
collection, analysis, profiling, banking, and DNA profile database maintenance.
Currently the Company plans to offer two services. The first being an in home
self test DNA Profile Kit with banking (storage). The initial price for this
service is currently US$120. The second service, performed by a professional,
allows for the collection, analysis, profiling, banking, and DNA profile
database maintenance. This service will assist the client in establishing a
chain of custody. Through this service the Company will provide secure access to
a client's personal DNA profile, with documented chain of custody established,
should at some point in the future the need arise to provide evidence of prior
ownership. The initial price for this service is currently US $280.


                                       10


<PAGE>


IN HOME SELF TEST DNA PROFILE KIT AND BANKING.

The Kit will contain buccal sample swabs, sample collection technique indicator,
pre-paid return envelope, a collection seal, along with easy to follow step by
step directions to take a sample.

The sample process of collection is simple, fast, and non-intrusive. Collection
takes place by way of a home self-test kit, where a cotton swab (a buccal swab)
is gently wiped across the inside of the Client's cheek. The swab, which
contains your saliva and the DNA sample, is then labeled and mailed to the
Company for banking (storage). The test process and results would not be
considered suitable for use in a court of law. A certificate with the owner's
name, reference and identification number and other information will be mailed
back to the client.

The reasons for the use of the in home self test DNA Profile Kit and banking
service would include the following: 1) storage of a person's DNA; 2) peace of
mind; 3) permanent identifier of family member's DNA; 4) a tool for
identification of missing persons; 5) a genetic history of an elder family
member that may provide clues to inherited diseases; and 6) other genetic
issues.

CHAIN OF CUSTODY DNA PROFILING AND BANKING

Upon receipt of the client's registration for the service, the Company will set
up a DNA sample collection appointment at a hospital, laboratory or clinic near
the client. At the time of collection, the client will be required to provide
identification in the form of birth certificate, social security card or drivers
license. A DNA sample will be collected by way of a buccal cheek swab and the
client will be fingerprinted and photographed. The sample will be labeled,
securely stored and then sent to an independent third party testing facility
where it will be analyzed and a DNA profile will be determined, thereby
establishing the DNA pattern in a format recognized by the international
scientific and legal communities. We currently intend to use Orchid Helix's
testing facilities to perform these services. We have no agreement with Orchid
Helix. This collection and testing procedure establishes a date and time of
submission as evidence of prior ownership. The sample will be sealed and, along
with the results, will be stored for a period of 20 years. The results will be
cross checked with our database for fraud and duplicate submissions and then
added to our database. The Company will provide the client with a DNA Profile
Bank Certificate outlining the results of the client's personal, unique and
original DNA profile.

Results from home DNA tests are normally not guaranteed admissible in a court of
law due to the lack of the "chain of custody". The chain of custody refers to
the legal requirements necessary to establish and document the various persons
and methods used to handle and process the individual sample. A legally
admissible "chain of custody" for a sample requires the samples to be collected
in the presence of a third neutral party at a lab or hospital facility where all
parties are photographed to verify their identity.

The reasons for the use of the Chain Of Custody DNA Profiling and Banking
service would include the following; 1) Use as evidence of DNA theft or
misappropriation; 2) Proof of prior ownership; 3) Maternity or paternity cases;
or 4) Forensic cases.

We estimate the entire DNA Process for either of the services will take
approximately four to eight weeks from the time of DNA sample collection.

These services will be charged by debit or credit card or purchased by cashier's
check or money order.

The instructions and examples on our website are intended to allow potential
consumers to quickly begin the DNA collection and profiling process for
establishing their personal and unique DNA profile.

We plan to process most orders online by online credit card or cybercash
systems. We currently are developing the ability to process online orders. In
addition we have researched the needs of our planned website functions and the
fees associated with the services needed to fulfill those needs.

Our website content will consist of information relating to the biotech
industry, in particular content dealing with cloning and its related ethical
issues. More expansive information may be developed in the future.


                                       11


<PAGE>


DNA CLONING
We believe the cloning issue is confusing and fraught with ethical concerns. We
plan to provide information to help simplify the issue and provide more
expansive information to familiarize persons concerned about the cloning issue
and protecting their personal DNA against cloning. The process of DNA
collection, analysis and profiling can be an invasive, frightening and confusing
process for many. We believe we can familiarize the potential client with the
required steps and the need for the Company's DNA profile and banking service

We believe it is extremely difficult to prevent a determined collector from
obtaining samples of DNA, since all complex living creatures constantly leave
traces of DNA throughout their environment in the form of hair, skin, saliva,
etc. However, we believe you can help deter persons who have illegally obtained
a sample of your DNA from trafficking in these samples, or in pursuing illegal
activities, such as cloning of the samples, by establishing your personal DNA
profile to show prior ownership.

DISTRIBUTION

We plan to deliver our services through our website. As of the date of this
prospectus, we have an Internet service provider, web site developer and a basic
web site, all of which will be necessary to execute our plan of business. We
plan to establish our market through email advertising and through licensing the
service to third parties on a geographic basis; that is, we will grant licenses
to persons or business entities to offer our services in certain, specific
geographic areas, such as, the Province of Alberta, Canada or the State of
Texas. We have not yet established any specific geographic areas, and intend to
do so only when we have a third party interested in obtaining a license for a
specific area. We do not currently have any licenses or licensees, and have not
been in contact with or negotiated with anyone for any such license. We have not
conducted any market testing to determine the size of the market for our
services.

On July 15, 2003, we entered into a license agreement with Mr. Matt Sutton
whereby we granted him a non-exclusive license to market services relating to
the collection of DNA samples and related data. The agreement is for a term of
one (1) year, commencing August 15, 2003, and the license fee due under the
agreement is US$2,000.00 per month. The agreement with Mr. Sutton has terminated
and will not be renewed. Mr. Sutton made no sales of the Company's services. The
license for Mr. Sutton was not renewed because he decided to pursue other
business interests. We do not believe this lack of renewal will have any
material impact on the Company. As of March 31, 2005 the Company has received
fourteen (14) orders, and sold and received full payment for fourteen (14) of
its In Home Self Test Kit. The most recent sale date for an In Home Self Test
Kit was March 2005.

NEW PRODUCTS OR SERVICES.

Other than the services described in this prospectus, we currently have no new
products or services announced or planned to be announced to the public.

COMPETITIVE BUSINESS CONDITIONS

We will face competition from all aspects of the emerging DNA-related business
and industry. We will compete with pharmaceutical and other science or
technology-related companies that have superior DNA-related experience and/or
services which they now, or may, in the future, offer to their potential or
existing customers. Many of these companies may in time offer free information
and DNA-related storage facilities to their customers. Many of these companies
have other sources of revenues and we rely only on the fees generated through
our proposed DNA information and database services. In addition, these companies
may have better marketing and distribution channels. There can be no assurance
that we will be able to compete effectively in this highly competitive industry,
which could have a material adverse impact upon market acceptance of our
proposed business.

Our main, existing and potential competitors for our proposed DNA testing,
profiling and banking business are any business in the pharmaceutical business
or distribution of pharmaceutical products business. Some of the primary DNA
service and information providers and competitors are: DNA Testing Centre, Inc.
- www.dnatestingcentre.com, GeneTree DNA Testing Center - www.genetree.com,
Metaphase Genetics - www.metaphasegenetics.com, and Genex Diagnostics SwabTest -
www.swabtest.com, and DNA Diagnostic Center - www.dnacenter.com


                                       12


<PAGE>


OUR COMPETITIVE POSITION

We believe competition takes place on many levels, including pricing,
convenience in obtaining information, specialization, and breadth of services
offered. We intend to serve as a content aggregator for DNA-related information
on the Internet, and provide what we believe is an unbiased comprehensive
information source, as well as marketplace and facilitator for DNA-related
information.

Our objective is to provide a service that helps the consumer cut through the
often perceived clutter, confusion and noise of the marketplace and help them
confidentially and quickly bring each person to a point where they can make an
informed decision if the services offered are appropriate for them.

Within the industry, we will attempt to brand our website www.yourcloneguard.com
as the consumer's partner in his or her search for the most reliable DNA
collection, profiling, databank and information source. We will attempt to
provide the consumers with a one-stop shopping destination where they can access
information and decision support tools, such as any related news on topics
relating to DNA. However, we have no assurance we will be successful in
differentiating ourselves from our competitors, or that we will be successful in
providing acceptable services or competing in the marketplace for our services.
We will be using the Internet to advertise our services, by paying other
websites to place a link to our website on their website. We anticipate the cost
of this form of advertising will cost approximately $2,000 over the next 12
months.

By offering a specialized DNA storage and information service, we will be
targeting those consumers who are looking to establish their DNA profile and
banking of that profile. We believe that consumers will pay for a service that
is specialized, unbiased and comprehensive and one that helps them cut through
the perceived clutter, confusion and noise of the internet marketplace and help
them confidentially and quickly make an informed decision if the DNA testing and
profiling services offered are appropriate for them.

We expect that our operations will depend on a number of third parties over
which we will have limited control. Specifically, we do not plan to own an
Internet gateway, but instead we will rely on a third-party, independent and
unrelated Internet Service Provider to host our website. We may experience
interruptions in our website connection and our telecommunications access due to
our reliance upon third parties. This could result in loss of business and
revenues. We anticipate that we will use software that is dependent on an
operating system, database and server software developed and produced by and
licensed by independent third parties. We may discover errors and defects in
this third party software and rely on the third parties to correct these errors
and defects in a timely manner. Accordingly, continuous or prolonged
interruptions in our website connection or in our telecommunications access
would have an adverse effect upon consumer perception of our ability to provide
information in a timely and efficient manner.

A party who is able to circumvent our security measures could misappropriate
proprietary information and/or access our customers' DNA-related information and
data. We may be required to expend significant capital and other resources to
protect against security breaches or to alleviate problems caused by breaches.
Concerns over the security of Internet transactions and the privacy of users may
also inhibit the growth of the Internet generally, and the World Wide Web in
particular, especially as a means of conducting commercial transactions. To the
extent that our future activities or those of third party contractors whom we
may use involve the storage and transmission of proprietary information, such as
DNA-related information and data and credit card numbers, security breaches
could expose us to a risk of loss or litigation. There can be no assurance that
we will be able to implement security measures that will prevent security
breaches.

SOURCES AND AVAILABILITY OF RAW MATERIALS

As of the date of this prospectus, we have established initial contact with DNA
sample kit suppliers and DNA testing facilities. We have not entered into any
arrangement or agreements to date.


                                       13


<PAGE>


CUSTOMER BASE

As of May 9, 2005, the Company has received fourteen (14) orders, amounting to
$1680 in sales revenue, for its In Home Self Test Kit. We have received payment
in full of the $1680. We do not anticipate we will depend on one or a few major
customers. There can be no assurance that this assumption is correct.

Our intended principal market of customers is expected to be the people who are
aware of the problem with identity theft, those with concerns about the health
and health risk factors of their relatives and unborn children and those wishing
to preserve their DNA profile in a data bank for future uses. We intend to
target this market using internet advertising and promotion of our website
through links on other health- related websites, which we currently anticipate
will cost us approximately $2,000 over the next 12 months. Although we cannot
clearly determine or identify those who may see our marketing efforts or seek
our services, we believe that persons visiting these websites could be included
in our target market. We do not feel that the costs to advertise and market
through the internet is a barrier to our entry. We have not performed any
marketing studies to assess whether a potential market exists for our proposed
services, but we believe that there is such a market based on the existence of
other web-based data banks and the number of articles about DNA storage and
identity theft management has seen in the media. We do not intend to perform any
marketing studies prior to beginning operations. Based on the costs of similar
services, we believe we can sustain a market for our services.

INTELLECTUAL PROPERTY

We have recently applied for a service mark for "yourcloneguard". We do not have
any trademarks, patents, licenses, royalty agreements, or other proprietary
interests, except for the web domain name: yourcloneguard.com.

GOVERNMENTAL REGULATION ISSUES

We are not now affected by direct government regulation. Based on our research,
we do not believe the products and services we intend to offer require approval
from the Food and Drug Administration. However, we are affected by laws, rules
and regulations directly applicable to access to or commerce on the Internet
generally. However, due to increasing usage of the Internet, a number of laws
and regulations may be adopted relating to the Internet, covering user privacy,
pricing, and characteristics and quality of products and services. Furthermore,
the growth and development for Internet commerce may prompt more stringent
consumer protection laws imposing additional burdens on those companies
conducting business over the Internet. The adoption of any additional laws or
regulations may decrease the growth of the Internet, which, in turn, could
decrease the demand for Internet services and increase the cost of doing
business on the Internet. These factors may have an adverse effect on our
business, results of operations and financial condition.

Moreover, the interpretation of sales tax, libel and personal privacy laws
applied to Internet commerce is uncertain and unresolved. We may be required to
qualify to do business as a foreign corporation in each state or foreign
country. Our failure to qualify as a foreign corporation in a jurisdiction where
we are required to do so could subject us to taxes and penalties. Any existing
or new legislation or regulation, including state sales tax, or the application
of laws or regulations from jurisdictions whose laws do not currently apply to
our business, could have a material adverse effect on our business, results of
operations and financial condition.

MARKETING RESEARCH AND DEVELOPMENT

To date, we have spent $10,000 on marketing research and development of our
website.

ENVIRONMENTAL LAW COMPLIANCE

To the extent which environmental compliance may be necessary, we do not
anticipate any significant compliance expense.


                                       14


<PAGE>


EMPLOYEES.

The Company does not have any employees.

REPORTS TO SECURITY HOLDERS.

As of February 11, 2005 the Company became effective and is a reporting company
under the requirements of the Exchange Act and will file quarterly, annual and
other reports with the Securities and Exchange Commission. Our annual report
will contain the required audited financial statements. We are not required to
deliver an annual report to security holders and will not voluntarily deliver a
copy of the annual report to the security holders. The reports and other
information filed by us will be available for inspection and copying at the
public reference facilities of the Commission, 450 Fifth Street, N.W.,
Washington, D.C. 20549.

Copies of the material may be obtained by mail from the Public Reference Section
of the Commission at 450 Fifth Street, N.W., Washington, D.C. 20549, at
prescribed rates. Information on the operation of the Public Reference Room may
be obtained by calling the SEC at 1-800-SEC-0330. In addition, the Commission
maintains a World Wide Website on the Internet at http://www.sec.gov that
contains reports, proxy and information statements and other information
regarding registrants that file electronically with the Commission.

PLAN OF OPERATIONS

The discussion contained in this prospectus contains "FORWARD-LOOKING
STATEMENTS" that involve risk and uncertainties. These statements may be
identified by the use of terminology such as "BELIEVES," "EXPECTS," "MAY,"
"SHOULD" or "ANTICIPATES" or expressing this terminology negatively or similar
expressions or by discussions of strategy. The cautionary statements made in
this prospectus are applicable to all related forward-looking statements
wherever they appear in this prospectus. Our actual results could differ
materially from those discussed in this prospectus. Important factors that could
cause or contribute to these differences include those discussed under the
caption entitled "RISK FACTORS," as well as those discussed elsewhere in this
registration statement.

We are a development stage company with limited operations or revenues. We are
unable to satisfy cash requirements without management's financial support or
other funding. Our management and certain investors have made $149,975 of
capital contributions to our business. The Company has raised the total of
$99,975 through Private Placements (see page 32 of the SB-2 filing "Recent Sales
of Unregistered Securities") and in January of 2004 the Company issued two
convertible debentures in the principal amount of $25,000 each, at an interest
rate of 10% per annum, for a total principal amount of $50,000 to two separate
unrelated non-US parties. We anticipate, but have no assurance, that we may need
to meet our cash requirements for the foreseeable future through the financial
support of our management. Management's capital contributions will be
accomplished through interest bearing promissory notes between our company and
management. We have not determined the amount of funds that will be necessary
for management to contribute at this time. Nor is there any assurance our
management will have funds available to loan us as and when we require funds. In
this event, we will be required to seek loans and/or equity funding from third
parties, and there is no assurance we will be able to do so.

The Company's website will be used as a marketing and sales tool. It is intended
to outline the features and the benefits of the DNA collection and profile
service as well as acting as an information resource. The instructions and
examples on our website are intended to allow potential consumers to quickly
begin the DNA collection and profiling process for establishing their personal
and unique DNA profile.

We anticipate that most orders for our services will occur by online credit card
or cybercash systems. We can take orders online through our order form and are
currently developing the ability to process online orders.

Over the next twelve months, we plan to further develop our website
www.yourcloneguard.com to provide additional DNA related information.
Specifically, during the next 12 months, we anticipate focusing our efforts on
the following specific areas of operations:

         1. Internet marketing
         2. Maintaining and enhancing content of website
         3. Licensing agreements
         4. DNA information and services


                                       15


<PAGE>


In the event we need to raise additional funds, we have not yet determined how,
where or when we will obtain these funds. There is no assurance that we will be
able to obtain financing for our business development, if, as and when required,
or on terms favorable to the Company. If adequate funds are not available to us,
we believe that our business development could be adversely affected. To sustain
operations over the next 12 months we are anticipating total operational expense
of $14,000 made up as follows $2000 internet advertising and promotion, and
$12,000 for marketing and operational expenses.

As of March 31, 2005 the Company had available cash in the amount of $11,914 and
accounts receivables in the amount of $2,000. Our cash will be used to fund
operations until approximately the end of December 2005. During the period prior
to December 2005, the Company may, nevertheless, need to seek additional funding
in the form of equity or debt to meet unanticipated expenses.

Our future capital requirements will also depend on one or more of the following
factors: - market acceptance of our services; - the extent and progress of our
research and development programs; - competing technological and market
developments; and - the costs of commercializing our services.

There can be no assurance that funding will be available on favorable terms to
permit successful commercialization of our DNA services or be successful in our
proposed business operations.

In addition, we have no further credit facility or other committed sources of
capital. We may be unable to establish credit arrangements on satisfactory
terms, if at all. If capital resources are insufficient to meet our future
capital requirements, we may have to raise additional funds to continue
development of our website. There can be no assurance that the funds will be
available on favorable terms, if at all.

To the extent that additional capital is raised through the sale of equity
and/or convertible debt securities, the issuance of the securities will likely
result in dilution to our shareholders.

Our website is fully developed, operational and is producing revenue. The total
cost for developing our website was $2,157. We anticipate we will generate
revenues from the accumulation of customer's DNA information and data, in a
legal state, to the website, and through the sale of advertisements. There is no
assurance that we will be successful in the marketing our DNA profile services
or licensing. We have no other proposed sources of revenue. Therefore, if we are
not successful in this regard, we will be unable to achieve revenues under our
current business plan.

If our company or its management receives proceeds from the sales of the
securities by the selling security shareholders, which neither the company nor
its management has any intent to do, those persons may have conducted an illegal
distribution of our securities and may be deemed underwriters. Accordingly, they
will have liability for any material misrepresentations or omissions in this
document and otherwise in the offer and sale of securities.

We do not anticipate significant research and development expenses over the next
twelve months. We do not expect to purchase or sell any plant and significant
equipment or make any significant changes in the number of employees over the
next twelve months.

DESCRIPTION OF PROPERTY

We do not own any real property at this time, and we conduct our business from
an office at 2890 Vassar Street, Suite A, Reno, NV 89502. We are sharing a small
office space at no cost with an unrelated third party. This is a competitive
rate for similar space in the area.

The Company believes that existing facilities are adequate for its needs through
December 2005. Should the Company require additional space at that time, or
prior thereto, the Company will attempt to secure space can on commercially
reasonable terms and without undue operational disruption.


                                       16


<PAGE>


PART II       OTHER INFORMATION

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.

EXHIBITS

a) Reports on Form 8-K: No reports were on filed on Form 8K during the quarter
ended March 31, 2005.


EXHIBIT NO.       DOCUMENT DESCRIPTION


     31.1         Certifications by Art Bandenieks, Chief Executive Officer
                  required by Rule 13a-14(a)

     31.2         Certification by Lee Southern, Chief Financial Officer
                  required by Rule 13a-14(a)

     32.1         Certification by Art Bandenieks pursuant to Section 906 of the
                  Sarbanes-Oxley Act of 2002

     32.2         Certification by Lee Southern pursuant to Section 906 of the
                  Sarbanes-Oxley Act of 2002


ITEM 7. SIGNATURES


                                   SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused
this report to be signed on its behalf by the undersigned, thereunto duly
authorized.


                             BV PHARMACEUTICAL, INC.



DATE: May 10, 2005           By: /s/ ART BANDENIEKS
                                     ______________________________________
                                     Art Bandenieks, President and Director


                                       17